Affiliation:
1. Umm Al-Qura University College of Pharmacy
2. University of Birmingham College of Medical and Dental Sciences
3. The Dudley Group NHS Foundation Trust
Abstract
Abstract
Background
The adverse effects of antipsychotics on cardiometabolic function are well documented despite their known effectiveness. Despite guidelines promoting routine monitoring, practices appear to be suboptimal.
Aim
The present study investigated the level of adherence to guidelines for cardiovascular and metabolic monitoring among healthcare professionals in primary care and factors that may influence monitoring patterns.
Method
Data were collected for patients with mental illness and prescribed antipsychotics at two general practices in England (February 2016-February 2021). The main outcome measures were the proportion of patients with evidence of monitoring for cardiometabolic parameters (body compositions, anthropometrics, lipids, glucose outcomes). Regression analysis was used to explore the factors predicting the monitoring practices.
Results
Data from 497 patients were included. The proportion of patients receiving cardiometabolic monitoring at least once yearly varied across different parameters. Patients were mostly monitored for BP (92%), body weight (BMI; >85%) and HDL (72%), but to a lesser extent for other lipid parameters (non-HDL ≈ 2%) and blood glucose (≈ 2%). Old age (OR:2.0–7.0, p < 0.001) and chronic conditions (e.g., CVD and DM, p < 0.05) were associated with cardiometabolic monitoring. Conversely, high metabolic risks antipsychotics (olanzapine), antipsychotic polypharmacy and cardiometabolic dysregulations (e.g., dyslipidaemias) did not improve monitoring practices.
Conclusions
Cardiometabolic health monitoring was generally infrequent, irregular, and did not change in response to abnormal test results or antipsychotic treatment with high cardiometabolic risks, suggesting more efforts need to be made to ensure the guidelines for cardiometabolic monitoring are followed. Monitoring Practices need to be evaluated across more general practices in the UK.
Publisher
Research Square Platform LLC
Reference24 articles.
1. Correll CU, Solmi M, Veronese N et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry [Internet]. 2017 Jun 1 [cited 2021 Mar 19];16(2):163–80. Available from: https://onlinelibrary.wiley.com/doi/10.1002/wps.20420.
2. Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from prevenTable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ [Internet]. 2013 May 21 [cited 2019 Jun 11];346:f2539. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23694688.
3. Oteri A, Mazzaglia G, Pecchioli S et al. Prescribing pattern of antipsychotic drugs during the years 1996–2010: a population-based database study in Europe with a focus on torsadogenic drugs. Br J Clin Pharmacol [Internet]. 2016 Aug [cited 2019 Jun 11];82(2):487–97. Available from: http://doi.wiley.com/10.1111/bcp.12955.
4. Leslie DL, Mohamed S, Rosenheck RA. Off-Label Use of Antipsychotic Medications in the Department of Veterans Affairs Health Care System. Psychiatr Serv [Internet]. 2009 Sep [cited 2019 Jun 11];60(9):1175–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19723731.
5. Chang S-C, Lu M-L. Metabolic and Cardiovascular Adverse Effects Associated with Treatment with Antipsychotic Drugs. Clin Exp Dent Res [internet]. 2012 Apr 1 [cited 2018 Jul 9]; 4(2):103-7. Available from: https://www.nature.com/articles/nrendo.2011.156.